Taiwan · Delayed Price · Currency is TWD TWi Biotechnology Company Description
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan.
The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; AC- 1101, which is in Phase Ib trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases; and NORA520, an oral prodrug, which is hydrolyzed to Brexanolone.
It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets.
TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan. TWi Biotechnology, Inc. operates as a subsidiary of Xinchen Investment Company.
| Country | Taiwan |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Chen-En Tsai |
Contact Details
Address: No. 41, Lane 221 Taipei, 114723 Taiwan | |
| Phone | 886 2 2657 1788 |
| Website | twibiotech.com |
Stock Details
| Ticker Symbol | 6610 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006610009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Chen-En Tsai M.D., Ph.D. | President and Chief Medical Officer |
| Dr. Chih-Ming Chen Ph.D. | Founder |
| Li Juan Huang | Accounting Supervisor |
| Guang-Wei Lu Ph.D. | Senior Vice President of Research & Development |
| Dr. Michelle Chen Ph.D. | Head of Business Development |